represents a premium of approximately 32.9% over the closing price on September 11, 2012 and a 33.4% premium over the 30-trading day volume-weighted average closing price on September 11, 2012, the last trading day prior to the Company's announcement on September 12, 2012 that it had received a "going private" proposal from Dr. Jing Lou
, chairman and chief executive officer of 3SBio, and CPEChina Fund, L.P., a China
-focused private equity fund associated with CITIC Private Equity Funds Management Co. Ltd. ("CITIC PE" and together with Dr. Jing Lou
and the other Rollover Shareholders, the "Buyer Group"). Collectively, the Consortium Shares owned by the Buyer Group represent approximately 18.1% of the Company's total issued and outstanding share capital.
Parent intends to finance the merger through a combination of debt, equity and cash in the Company. Parent has entered into a facility agreement pursuant to which China CITIC Bank International Limited has agreed to provide debt financing for the transaction. CITIC PE has provided equity commitment. Dr. Jing Lou and CITIC PE each entered into a limited guaranty in favor of the Company.
The Company's Board of Directors, acting upon the unanimous recommendation of an independent committee formed by the Board of Directors (the "Independent Committee"), approved the Merger Agreement and the merger contemplated in the Merger Agreement and resolved to recommend that the Company's shareholders vote to approve and authorize the Merger Agreement and the merger. The Independent Committee, which is composed solely of independent directors unrelated to Parent, Merger Sub or any of the management members of the Company, negotiated the terms of the Merger Agreement with the assistance of its legal and financial advisors.
The merger contemplated in the Merger Agreement, whPage: 1 2 3 4 5 6 Related biology technology :1
. 3SBio Inc. to Present at the UBS Greater China Conference 20122
. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 20113
. 3SBio Inc. Announces Unaudited First Quarter 2012 Results4
. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife5
. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public6
. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine7
. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy8
. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah9
. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart10
. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award11
. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies